Literature DB >> 23683390

Meta-analysis of oxidative stress in schizophrenia.

Joshua Flatow1, Peter Buckley, Brian J Miller.   

Abstract

BACKGROUND: Schizophrenia is associated with impaired antioxidant defense, including abnormal serum, plasma, and red blood cell (RBC) oxidative stress parameters. We performed a meta-analysis of these associations, considering the effect of clinical status and antipsychotic treatment after an acute exacerbation of psychosis.
METHODS: We identified articles by searching PubMed, PsychInfo, and Institute for Scientific Information, and the reference lists of identified studies.
RESULTS: Forty-four studies met the inclusion criteria. Total antioxidant status seemed to be a state marker, because levels were significantly decreased in cross-sectional studies of serum and plasma in first-episode psychosis (FEP) and significantly increased in longitudinal studies of antipsychotic treatment for acute exacerbations of psychosis (p < .01 for each). The RBC catalase and plasma nitrite seemed to be state-related markers, because levels in cross-sectional studies were significantly decreased in FEP (p < .01) and significantly increased in stable outpatients (p = .01). In contrast, RBC superoxide dismutase seemed to be a trait marker for schizophrenia, because levels in cross-sectional studies were significantly decreased in acutely relapsed inpatients, FEP, and stable outpatients (p < .01 for each).
CONCLUSIONS: Oxidative stress abnormalities in FEP suggest an effect that might be independent of antipsychotic medications. Although some parameters (total antioxidant status, RBC catalase, and plasma nitrite) might be state markers for acute exacerbations of psychosis, others (RBC superoxide dismutase) might be trait markers; however, more longitudinal studies are needed. Our findings suggest that oxidative stress might serve as a potential biomarker in the etiopathophysiology and clinical course of schizophrenia.
Copyright © 2013 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antioxidants; first-episode psychosis; meta-analysis; oxidative stress; relapse; schizophrenia

Mesh:

Year:  2013        PMID: 23683390      PMCID: PMC4018767          DOI: 10.1016/j.biopsych.2013.03.018

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  147 in total

1.  Low concentration of nitrite and nitrate in the cerebrospinal fluid from schizophrenic patients: a pilot study.

Authors:  Jesus Ramirez; Rodrigo Garnica; Marie-Catherine Boll; Sergio Montes; Camilo Rios
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

2.  Metabolomic profiling to identify potential serum biomarkers for schizophrenia and risperidone action.

Authors:  Jiekun Xuan; Guihua Pan; Yunping Qiu; Lun Yang; Mingming Su; Yumin Liu; Jian Chen; Guoyin Feng; Yiru Fang; Wei Jia; Qinghe Xing; Lin He
Journal:  J Proteome Res       Date:  2011-11-08       Impact factor: 4.466

3.  A meta-analysis of oxidative stress markers in schizophrenia.

Authors:  Ming Zhang; ZhongMing Zhao; Lin He; ChunLing Wan
Journal:  Sci China Life Sci       Date:  2010-02-12       Impact factor: 6.038

4.  Smoking habits and plasma lipid peroxide and vitamin E levels in never-treated first-episode patients with schizophrenia.

Authors: 
Journal:  Br J Psychiatry       Date:  2000-03       Impact factor: 9.319

5.  Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia.

Authors:  K Brown; A Reid; T White; T Henderson; S Hukin; C Johnstone; A Glen
Journal:  Biol Psychiatry       Date:  1998-06-15       Impact factor: 13.382

6.  Potential effect of olanzapine on total antioxidant status and lipid peroxidation in schizophrenic patients.

Authors:  Basil M Al-Chalabi; Imad A J Thanoon; Faris A Ahmed
Journal:  Neuropsychobiology       Date:  2009-02-17       Impact factor: 2.328

7.  The relationship between serum uric acid concentration and metabolic syndrome in patients with schizophrenia or schizoaffective disorder.

Authors:  Chih-Chiang Chiu; Chun-Hsin Chen; Ming-Chyi Huang; Po-Yu Chen; Chang-Jer Tsai; Mong-Liang Lu
Journal:  J Clin Psychopharmacol       Date:  2012-10       Impact factor: 3.153

8.  Evidence for oxidative DNA damage in the hippocampus of elderly patients with chronic schizophrenia.

Authors:  Naoya Nishioka; Steven E Arnold
Journal:  Am J Geriatr Psychiatry       Date:  2004 Mar-Apr       Impact factor: 4.105

9.  Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics.

Authors:  Ganesh Dakhale; Suchet Khanzode; Shruti Khanzode; Anand Saoji; Linesh Khobragade; Avinash Turankar
Journal:  Neuropsychobiology       Date:  2004       Impact factor: 2.328

10.  Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study.

Authors:  Daisuke Matsuzawa; Takayuki Obata; Yukihiko Shirayama; Hiroi Nonaka; Yoko Kanazawa; Eiji Yoshitome; Junichi Takanashi; Tsuyoshi Matsuda; Eiji Shimizu; Hiroo Ikehira; Masaomi Iyo; Kenji Hashimoto
Journal:  PLoS One       Date:  2008-04-09       Impact factor: 3.240

View more
  162 in total

1.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

Review 2.  Inflammation and schizophrenia.

Authors:  Brian Kirkpatrick; Brian J Miller
Journal:  Schizophr Bull       Date:  2013-09-26       Impact factor: 9.306

3.  Sulforaphane Augments Glutathione and Influences Brain Metabolites in Human Subjects: A Clinical Pilot Study.

Authors:  Thomas W Sedlak; Leslie G Nucifora; Minori Koga; Lindsay S Shaffer; Cecilia Higgs; Teppei Tanaka; Anna M Wang; Jennifer M Coughlin; Peter B Barker; Jed W Fahey; Akira Sawa
Journal:  Mol Neuropsychiatry       Date:  2018-04-17

4.  Overview and systematic review of studies of microbiome in schizophrenia and bipolar disorder.

Authors:  Tanya T Nguyen; Tomasz Kosciolek; Lisa T Eyler; Rob Knight; Dilip V Jeste
Journal:  J Psychiatr Res       Date:  2018-01-31       Impact factor: 4.791

Review 5.  Oxidative stress and the antipsychotic-induced vacuous chewing movement model of tardive dyskinesia: evidence for antioxidant-based prevention strategies.

Authors:  Josh Lister; José N Nobrega; Paul J Fletcher; Gary Remington
Journal:  Psychopharmacology (Berl)       Date:  2014-04-22       Impact factor: 4.530

6.  Redox Dysregulation in Schizophrenia Revealed by in vivo NAD+/NADH Measurement.

Authors:  Sang-Young Kim; Bruce M Cohen; Xi Chen; Scott E Lukas; Ann K Shinn; A Cagri Yuksel; Tao Li; Fei Du; Dost Öngür
Journal:  Schizophr Bull       Date:  2016-09-24       Impact factor: 9.306

7.  Niflumic acid, a TRPV1 channel modulator, ameliorates stavudine-induced neuropathic pain.

Authors:  Lovish Marwaha; Yashika Bansal; Raghunath Singh; Priyanka Saroj; Rupinder Kaur Sodhi; Anurag Kuhad
Journal:  Inflammopharmacology       Date:  2016-10-18       Impact factor: 4.473

Review 8.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

9.  Redox Is a Global Biodevice Information Processing Modality.

Authors:  Eunkyoung Kim; Jinyang Li; Mijeong Kang; Deanna L Kelly; Shuo Chen; Alessandra Napolitano; Lucia Panzella; Xiaowen Shi; Kun Yan; Si Wu; Jana Shen; William E Bentley; Gregory F Payne
Journal:  Proc IEEE Inst Electr Electron Eng       Date:  2019-04-29       Impact factor: 10.961

Review 10.  Neurocognitive, Neuroprotective, and Cardiometabolic Effects of Raloxifene: Potential for Improving Therapeutic Outcomes in Schizophrenia.

Authors:  Mohammad M Khan
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.